SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 70.53 |
Enterprise Value ($M) | 105.83 |
Book Value ($M) | -34.79 |
Book Value / Share | -0.46 |
Price / Book | -2.03 |
NCAV ($M) | -38.84 |
NCAV / Share | -0.51 |
Price / NCAV | -1.82 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -2.10 |
Return on Assets (ROA) | -0.94 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 4.49 |
Current Ratio | 4.49 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 25.11 |
Assets | 29.16 |
Liabilities | 63.95 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
19,523 | 118,383 | 16.49 | |
58,030 | 153,441 | 37.82 | |
26,311 | 111,846 | 23.52 | |
(click for more detail) |
Similar Companies | |
---|---|
CARM – Carisma Therapeutics, Inc. | CGTX – Cognition Therapeutics, Inc. |
CHRS – Coherus BioSciences, Inc. | CLYM – Climb Bio, Inc. |
CMRX – Chimerix, Inc. |
Financial data and stock pages provided by
Fintel.io